SINTX Technologies Completes First Human Implant and Secures $10M for Commercial Rollout
SINTX Technologies completed the first human surgical procedure using its FDA-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System and appointed Ryan Elmore as President on March 16, 2026. The company raised $10 million in capital, divested non-medical assets, secured a supply deal with Evonik, and initiated AI-assisted 3D manufacturing.
1. Clinical Milestone
SINTX completed the first human surgical procedure using its FDA-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System, marking its entry into the foot and ankle reconstruction market and validating silicon nitride for orthopedic implants.
2. Leadership and Financial Strength
The company appointed Ryan Elmore as President on March 16, 2026 and strengthened its balance sheet with a $10 million capital raise, alongside divestiture of non-medical assets and recruitment of a healthcare-focused board to improve capital efficiency and strategic focus.
3. Platform Expansion and Partnerships
SINTX secured a supply agreement with Evonik Industries for SiNERGY silicon nitride/PEEK composite development, expanded its patent portfolio for antipathogenic textiles and wound care, and initiated AI-assisted 3D additive manufacturing supported by new equipment and technical hires.
4. Commercial Outlook and R&D
Management is targeting commercial rollout in 2026 across orthopedic applications, advancing preclinical animal studies for sutures, meshes and wound care, with plans to finalize preclinical data by H2 2026 and pursue additional partnerships to leverage its biomaterials platform.